𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer

✍ Scribed by Robert Milroy; Jeffrey Cummings; Stanley B. Kaye; Stephen W. Banham

Publisher
Springer
Year
1987
Tongue
English
Weight
298 KB
Volume
20
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

✦ Synopsis

4-Demethoxydaunorubicin (4-DMDNR) is an oral anthracycline with antitumour activity demonstrated in a number of clinical studies. We have assessed the usefulness of 4-DMDNR in 16 patients with advanced small cell lung cancer, none of whom had received previous chemotherapy. There were no complete or partial responders among the 14 evaluable patients, but 9 patients showed a minor radiographic improvement and 6 reported transient symptomatic improvement. Side effects were mostly minor or moderate, although one patient succumbed to septicaemia during neutropenia following treatment. There was no evidence of cardiotoxicity in any patient. Pharmacological studies were undertaken in 8 patients. A previously undescribed metabolite, identified as the 7-deoxyaglycone of 4-demethoxydaunorubicinol, was detected in 3 patients and these 3 patients all showed some anti-tumor response.

πŸ“œ SIMILAR VOLUMES

A phase II trial of oral 4β€² demethoxydau
A phase II trial of oral 4β€² demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer
✍ P. Presgrave; R. Woods; R. Kefford; D. Bell; D. Raghavan; J. Levi πŸ“‚ Article πŸ“… 1988 πŸ› Springer US 🌐 English βš– 216 KB

4' Demethoxydaunorubicin, an orally active daunorubicin analogue, was administered to 22 patients with inoperable non small cell lung cancer (NSCLC). Patients were stratified into good and poor risk categories and received doses of 45 mg/m 2 and 40 mg/m 2 respectively at 28 day intervals. All 22 pat

A phase II study of oral idarubicin (4-d
A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer
✍ Nicholas S. A. Stuart; Michael H. Cullen; Terrence J. Priestman; George R. P. Bl πŸ“‚ Article πŸ“… 1988 πŸ› Springer 🌐 English βš– 352 KB

Idarubicin (4-demethoxydaunorubicin: DMDNR) is an orally active analogue of daunorubicin that has shown promising activity in animal and early clinical studies. We gave idarubicin in a phase II study to patients with advanced breast cancer unresponsive to hormonal manipulation and in some cases to s